 BRYAN, Texas, May 04, 2021 GLOBE NEWSWIRE -- iBio, Inc. NYSEA:IBIO iBio or the Company, a biotech innovator and biologics contract manufacturing organization, announced today that it has successfully resolved its lawsuit with Fraunhofer USA, Inc. Fraunhofer USA. The parties settlement confirms iBios ownership of certain intellectual property related to plant-based biopharmaceutical production. As part of the settlement, iBio granted Fraunhofer USA a fully paid-up license to use the recombinant protein manufacturing technologies that were the subject of litigation. 